Home > Insider Trading > Filing (0001595585-20-000068)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595585	Tricida Inc.	TCDA	Pharmaceutical Preparations (2834)	463372526

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1748808	Parsell Dawn Otto	7000 Shoreline Court, Suite 201 South San Francisco CA 94080	Evp, Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-05-08	210	$1.68	465	No	4	M	Direct
Common Stock	Disposition	2020-05-08	210	$31.98	255	No	4	S	Direct
Common Stock	Acquisiton	2020-05-08	830	$1.68	1,085	No	4	M	Direct
Common Stock	Disposition	2020-05-08	830	$31.98	255	No	4	S	Direct
Common Stock	Acquisiton	2020-05-08	523	$7.49	778	No	4	M	Direct
Common Stock	Disposition	2020-05-08	523	$31.98	255	No	4	S	Direct
Common Stock	Acquisiton	2020-05-08	1,437	$2.39	1,692	No	4	M	Direct
Common Stock	Disposition	2020-05-08	1,437	$31.98	255	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-05-08	210	$0.00	210	$1.68
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-05-08	830	$0.00	830	$1.68
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-05-08	523	$0.00	523	$7.49
Common Stock	Employee Stock Option (right to buy)	Disposition	2020-05-08	1,437	$0.00	1,437	$2.39

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
420	2026-09-26	No	4	M	Direct
4,190	2026-11-02	No	4	M	Direct
23,033	2028-03-14	No	4	M	Direct
15,386	2027-09-13	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2019.
This option vested 25% on June 8, 2017, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.
This option vested 25% on October 1, 2017, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.
This option vests 25% on March 15, 2019, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.
This option vests 25% on September 1, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.